Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.72 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28755333 | 0.88 | MEN1 (0.58) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL410146 | 0.86 | TGFBR1 (0.68) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL412084 | 0.86 | MEN1 (0.57) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL1817920 | 0.86 | ALDH1A1 (0.68) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL1063104 | 0.86 | MEN1 (0.57) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL8104012 | 0.85 | MEN1 (1.00) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL408086 | 0.84 | CYP1A2 (0.72) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL413342 | 0.84 | CYP1A2 (1.00) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL414358 | 0.84 | CYP1A2 (1.00) | MEN1KMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL413202 | 0.83 | TGFBR1 (0.86) | MEN1KMT2ALMNAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107959-B1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | claimed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | claimed |
| CN-1152867-C | Quinazoline derivatives as medicaments | �����ɷ� | 2004-06-09 | — | — | CN | claimed |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2003-04-10 | — | — | US | claimed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | claimed |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2002-10-31 | — | — | US | claimed |
| JP-2002523502-A | — | — | 2002-07-30 | — | — | JP | claimed |
| CN-1333757-A | Quinazoline derivatives as medicaments | SCIOS INC (US) | 2002-01-30 | — | — | CN | claimed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | claimed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | claimed |
| WO-2000012497-B1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161010-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | MEN1 1621/4885KMT2A 2523/4885LMNA 2827/4885 |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | MEN1 1936/4885KMT2A 1871/4885LMNA 2788/4885 |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | MEN1 1621/4885KMT2A 2523/4885LMNA 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.